Moreover, since adiponectin has multiple antidiabetic, anti‐atherogenic effects, it would be crucial to explore whether a synergistic administration of GDF11 and adiponectin would further enhance the beneficial effects of this treatment in age‐related and metabolic disorders. This evidence concerns the gene GDF11 and metabolic disease.